StockData
Creative Medical Technology Holdings, Inc. logo

Creative Medical Technology Holdings, Inc. (CELZ) company profile

CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$0.53−0.09 (-14.35%)

Close on Nov 13, 2026Market cap $3.48MP/E –Yield –

About Creative Medical Technology

Biological Products, (No Diagnostic Substances), SIC 2836

Creative Medical Technologies Holdings, Inc. is a commercial-stage biotechnology company focused on advancing regenerative therapies across immunotherapy, endocrinology, urology, neurology, and orthopedics. The company develops cell-based technologies and therapeutic platforms, notably ImmCelz, an autologous reprogrammed immune cell therapy, and AlloStem, an allogeneic human perinatal tissue-derived cell program. Its clinical and development pipeline targets multiple indications, including chronic lower back pain caused by degenerative disc disease, type 1 diabetes, female infertility, and erectile dysfunction. In addition, the enterprise pursues biodefense and therapeutic modeling initiatives that combine induced pluripotent stem cells with artificial intelligence. Its operations serve clinical trial populations and patients suffering from chronic, debilitating, or autoimmune conditions.

The company conducts its clinical and research activities in the United States, operating through corporate subsidiaries such as Creative Medical Technologies, ImmCelz, and StemSpine. Its principal executive offices are located in Phoenix, Arizona.

Summary of the business section of Creative Medical Technology's latest annual report, written by StockData.

Company profile

Company

Legal name
Creative Medical Technology Holdings, Inc.
Founded
1998
Headquarters
Phoenix, AZ
Address
211 E. Osborn Rd. 85012
Phone
(480) 399-2822
Website
clinicaltrials.gov
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
Haynie, Salt Lake City, Utah

Stock & identifiers

Ticker
CELZ
Former tickers
JMRK until Aug 19, 2016
Exchange
Nasdaq
IPO date
Nov 6, 2015
Shares outstanding
7M, Aug 7, 2026
Public float
$4.63M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, Jun 12, 2023; 1-for-500 reverse, Nov 10, 2021; 1-for-150 reverse, Feb 3, 2020
SEC CIK
1187953
CUSIP
22529Y408
ISIN
US22529Y4089
FIGI
BBG000BCFRJ4
Share class FIGI
BBG001S924N1
EIN
87-0622284

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Timothy WarbingtonPresident & CEO, Director1,047,113
Acquisition Corp. CreativeDirector–
Michael H. FingerDirector351

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 13, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 11, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 14, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 7, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 2, 2021ListingRegistration of securities on an exchange (Form 8-A)
Mar 30, 2020Late filingNotification of late filing
May 15, 2019Late filingNotification of late filing
May 14, 2018Late filingNotification of late filing
Aug 15, 2016Late filingNotification of late filing
May 19, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 19, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
May 13, 2016Name changeName changed from JOLLEY MARKETING INC to Creative Medical Technology Holdings, Inc.
Mar 30, 2016Late filingNotification of late filing
Sep 30, 2015Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 16, 2012Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 13, 2012Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 22, 2009Auditor changeChange in certifying accountant (8-K Item 4.01)

See a number that looks wrong?